Abstract:Hearing loss is a major disability in everyday life and therapeutic interventions to protect hearing would benefit a large portion of the world population. Here we found that mice devoid of the protein kinase suppressor of RAS 1 (KSR1) in their tissues (germline KO mice) exhibit resistance to both cisplatin- and noise-induced permanent hearing loss compared to their wild-type KSR1 littermates. KSR1 is a scaffold protein that brings in proximity the mitogen-activated protein kinase (MAPK) proteins BRAF, MEK1/2 and ERK1/2 and assists in their activation through a phosphorylation cascade induced by both cisplatin and noise insults in the cochlear cells. KSR1, BRAF, MEK1/2, and ERK1/2 are all ubiquitously expressed in the cochlea. Deleting the KSR1 protein tempered down the MAPK phosphorylation cascade in the cochlear cells following both cisplatin and noise insults and conferred hearing protection of up to 30 dB SPL in three tested frequencies in male and female mice. Treatment with dabrafenib, an FDA-approved oral BRAF inhibitor, protected male and female KSR1 wild-type mice from both cisplatin- and noise-induced hearing loss. Dabrafenib treatment did not enhance the protection of KO KSR1 mice, providing evidence dabrafenib works primarily through the MAPK pathway. Thus, either elimination of the KSR1 gene expression or drug inhibition of the MAPK cellular pathway in mice resulted in profound protection from both cisplatin- and noise-induce hearing loss. Inhibition of the MAPK pathway, a cellular pathway that responds to damage in the cochlear cells, can prove a valuable strategy to protect and treat hearing loss.Significance StatementTen percent of the world population suffers from hearing loss but this impairment may be preventable. We show that mice devoid of the KSR1 protein (KO) exhibit resistance to cisplatin- and noise-induced permanent hearing loss compared to wild-type littermates that harbor the protein. Removing KSR1 tempers down the MAPK phosphorylation cascade of BRAF-MEK-ERK induced in the cochlea following cisplatin and noise insults. Treatment of KSR1 wild-type mice following cisplatin or noise with an FDA-approved BRAF inhibitor, dabrafenib, protected the hearing and, importantly, did not confer additional protection to the KO KSR1 mice. Hence, the MAPK pathway has a unique role in responding to cochlear damage and removing KSR1 gene expression or drug inhibition of the pathway results in hearing protection.

Specific knockdown of <i>Htra2</i> by CRISPR-CasRx prevents acquired sensorineural hearing loss in mice

Prevention of acquired sensorineural hearing loss in mice by in vivo <i>Htra2</i> gene editing

Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing

Genetic Correction of TRMU Allele Restored the Mitochondrial Dysfunction-Induced Deficiencies in Ipscs-Derived Hair Cells of Hearing-Impaired Patients.

Treatment of autosomal recessive hearing loss via in vivo CRISPR/Cas9-mediated optimized homology-directed repair in mice

Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing

Precise Detection of CRISPR-Cas9 Editing in Hair Cells in the Treatment of Autosomal Dominant Hearing Loss

Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo

Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor

Adeno-associated Virus Vector Enables Safe and Efficient Cas9 Activation in Neonatal and Adult Cas9 Knockin Murine Cochleae

Single and Dual Vector Gene Therapy with AAV9-PHP.B Rescues Hearing in Tmc1 Mutant Mice

Characterization of promoters for adeno-associated virus mediated efficient Cas9 activation in adult Cas9 knock-in murine cochleae

Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss

In vivo outer hair cell gene editing ameliorates progressive hearing loss in dominant-negative Kcnq4 murine model

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents

The applications of CRISPR/Cas-mediated genome editing in genetic hearing loss

KSR1 Knockout Mouse Model Demonstrates MAPK Pathway’s Key Role in Cisplatin- and Noise-Induced Hearing Loss

Clarin-2 gene supplementation durably preserves hearing in a model of progressive hearing loss

Conditional overexpression of neuritin in supporting cells (SCs) mitigates hair cell (HC) damage and induces HC regeneration in the adult mouse cochlea after drug-induced ototoxicity

Protection Against Aminoglycoside-induced Ototoxicity by Regulated AAV Vector|[ndash]|mediated GDNF Gene Transfer Into the Cochlea

Gene editing in a Myo6 semi-dominant mouse model rescues auditory function